Home > News > Latest > FDA Calls Cara Therapeutics (CARA)' Kidney Disease Drug a Breakthrough, Stock Soars

FDA Calls Cara Therapeutics (CARA)' Kidney Disease Drug a Breakthrough, Stock Soars

Shares of pain-relief company Cara Therapeutics (CARA) are up more than 16 percent this morning after the company grabbed the Breakthrough Therapy Designation for its chronic kidney disease treatment CR845.Cara’s treatment is designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. The Federal Drug Administration granted the designation for patients with moderate-to-severe uremic pruritus (UP) in chronic kidney disease (CKD) patients undergoing hemodialysis.

Spotlight

Other News

Dom Nicastro | April 03, 2020

More Trending news

FDA Calls Cara Therapeutics (CARA)' Kidney Disease Drug a Breakthrough, Stock Soars

Spotlight

Other News

Spotlight

Resources

The Cardinal Health™ InteLogix™ Platform

A pragmatic approach to developing rare disease drug

The Globalization Of The Pharmaceutical Industry

The Cardinal Health™ InteLogix™ Platform

A pragmatic approach to developing rare disease drug

The Globalization Of The Pharmaceutical Industry